Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-4 of 4 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-4 of 4 studies
-
Anti-InfectiveCompleted with Results
Safety Study of Azithromycin in Cystic Fibrosis Patients Negative for P. aeruginosa , protocol number AZ 0004 (Open-Label)This study was an open-label extension study of the Azithromycin study in adolescents and children with CF who were not infected with P. aeruginosa. This study provided addiitonal information regarding the safety of longer term treatment.
-
Age:
6 Years to 18 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
30% or greater
-
Number of Visits:
3
-
Length of Participation:
24 weeks
-
-
Anti-InfectiveCompleted with Results
TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15This study evaluated the effect of adding oral azithromycin to inhaled tobramycin in people with CF who are chronically infected with P. aeruginosa.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 100%
-
Number of Visits:
5
-
Length of Participation:
14 weeks
-
-
Anti-InfectiveCompleted with Results
OPTIMIZE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin , protocol number OPTIMIZE-IP-12This study evaluated the effect of treatment with tobramycin inhalation solution (TIS) with and without azithromycin in people with CF who had their first isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture (or their first culture after being negative for Pa for at least 2 years).
-
Age:
6 Months to 18 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
18 months
-
-
Anti-InfectiveCompleted with Results
Azithromycin in patients with CF who are culture negative for Pseudomonas aeruginosa , protocol number AZ 0004 (Randomized)This study evaluated the effect of azithromycin in children with CF who are not infected with Pseudomonas aeruginosa.
-
Age:
6 Years to 18 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50% or greater
-
Number of Visits:
5
-
Length of Participation:
24 weeks
-
Showing 1-4 of 4 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More